

WHAT IS CLAIMED IS:

1. A method of preventing or treating otic disorders and otic-disorder-related complications in a subject comprising administering to the
5 subject a Cox-2 inhibitor.

2. The method according to claim 1, wherein the Cox-2 inhibitor is administered to the subject in combination with one or more otic agents.

3. The method according to claim 1, wherein the Cox-2 inhibitor comprises a non-steroidal anti-inflammatory drug.

10 4. The method according to claim 1, wherein the Cox-2 inhibitor comprises a Cox-2 selective inhibitor.

5. The method according to claim 4, wherein the Cox-2 selective inhibitor comprises at least one compound that is selected from the group consisting of celecoxib, parecoxib, deracoxib, valdecoxib,
15 etoricoxib, meloxicam, rofecoxib, lumiracoxib, prodrugs of any of them, and mixtures thereof.

6. The method according to claim 4, wherein the Cox-2 selective inhibitor comprises celecoxib.

7. The method according to claim 4, wherein the Cox-2
20 selective inhibitor comprises a chromene Cox-2 selective inhibitor.

8. The method according to claim 7, wherein the chromene Cox-2 selective inhibitor comprises at least one compound selected from the group consisting of

25 (S)-6-chloro-7-(1,1-dimethylethyl)-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
(2S)-6,8-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
(2S)-6-chloro-8-methyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
(2S)-8-ethyl-6-(trifluoromethoxy)-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid,
30 (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid,
(2S)-6-chloro-5,7-dimethyl-2-(trifluoromethyl)-2H-chromene-3-carboxylic acid, and mixtures thereof.

9. The method according to claim 2, wherein the otic agent comprises at least one compound selected from the group consisting of antibiotics, antifungals, corticosteroids, astringents, anticholinergics, antiseptics, antivirals, decongestants, antihistamines, anaesthetics, and mixtures thereof.

10. The method according to claim 2, wherein the otic agent comprises at least one compound selected from the group consisting of acyclovir, gancyclovir, interferons, mono and polyclonal antibodies, thimerasol, idoxuridine, vidarabine, trifluridine, famciclovir, valacyclovir, penciclovir, ganciclovir, dipyridamole, impulsin, pleconaril, foscarnet, ribavirin, amantadine, rimantadine, cidofovir, ICI 130,685, zanamivir, oseltamivir, valganciclovir, aciclovir, idoxuridine, vidarabine, valacyclovir, benzocaine, butamben picrate, tetracaine, dibucaine, carbocaine, cocaine, chloroprocaine, mepivacaine, etidocaine, prilocaine, etidocaine, bupivacaine, lidocaine, benzocaine plus antipyrine, fenamates, pyrrolealkanoic acids, pyrazolone derivatives, oxicams, pramoxine, azatadine, meclizine, promethazine bromodiphenhydramine, brompheniramine, brompheniramine maleate, carbinoxamine, chlorpheniramine, dexchlorpheniramine, diphenhydramine, doxylamine, phenindamine, pheniramine, phenyltoloxamine, pyrilamine, triprolidine, clemastine, dimenhydrinate, cetirizine, terfenadine, astemizole, loratadine, acrivastine, hydroxyzine, meclozine, compazine, imipramine, doxopin, amitryptoline, tripelennamine, fexofenadine, azatadine, ephedrine, ephinephrine, levodesoxyephedrine, oxymetazoline, naphazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, xylometazoline, acetic acid, boric acid, gentian violet, hydrogen peroxide, carbamide peroxide, chlorhexidine, saline, mercurochrome, povidone iodine, polyhyroxine iodine, cresylate, aluminum acetate, isopropyl alcohol, ethanol, propylene glycol, hydrocortisone, prednisone, fluprednisolone, dexamethasone, betamethasone, betamethasone valerate, methylprednisolone, fluocinolone acetonide, flurandrenolone acetonide, fluorometholone, cortisone, prednisolone, alclometasone, amcinonide,

betamethasone, clobetasol, clocortolone, desonide, desoximetasone, diflorasone, fluocinonide, flurandrenolide, fluticasone, halcinonide, halobetasol, mometasone, flumethasone, prednicarbate, triamcinolone, clotrimazole, griseofulvin, undecylenic, econazole, miconazole,

5 ketaconazole, sulconazole, oxiconazole, fluconazole, itraconazole, nystatin, naftifine, terbinafine, ciclopirox, butenafine, haloprogin, tolnaftate, penicillin, penicillin G, penicillin V, clavulanic acid, clavulanic acid plus amoxycillin, procaine, benzathine, cloxacillin, dicloxacillin, methicillin, nafcillin, oxacillin, azlocillin, carbenicillin, piperacillin, piperacillin plus

10 tazobactam, ticarcillin, mezlocillin, cefadroxil, cefazolin, cephalixin, cephalothin, cephalirin, cephradine, cefaclor, cefamandole, cefmetazole, cefonicid, cefotetan, cefoxitin, cefprozil, cefuroxime, loracarbef, cefepime, cefixime, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, Imipenem, meropenem, aztreonam, clavulanic

15 acid, sulbactam, tazobactam, ampicillin, ampicillin plus sulbactam, amoxycillin, amoxicillin, clavulanate potassium, amoxicillin plus clavulanate potassium, bacampicillin, clavulanic acid plus amoxycillin, aztreonam, imipenem, streptomycin, kanamycin, neomycin, gentamycin, tobramycin, amikacin, netilmicin, gentamicin, vancomycin, clindamycin,

20 azithromycin, clarithromycin, clindamycin, roxithromycin, dirithromycin, spiramycin, josamycin, erythromycin, lincomycin, bacitracin, colistin, polymyxin B, bacitracin, amphotericin, nystatin, rifampicin, tetracycline, chlortetracycline, oxytetracycline, demeclocycline, minocycline, doxycycline, chloramphenicol, ciprofloxacin, enoxacin, grepafloxacin,

25 levofloxacin, lomefloxacin, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, cinoxacin, nalidixic acid, clindamycin, linezolid, spectinomycin, quinupristin, quinupristin plus dalfopristin, dalfopristin, trimethoprim, trimethoprim-sulfamethoxazole, sulfanilamide, sulfadiazine, sulfamethoxazole, sulfisoxazole, sulfamethizole, silver sulfadiazine,

30 neopsporin, tobramycin, tobramycin plus dexamethasone, m-cresyl acetate, bis-(2-pyridyl-1-oxide) disulfide, botulinum toxin, Burrow's

Solution, Burrow's Solution plus acetic acid, mycelelex cream, mycolog cream, acetaminophen, mafenide, and mixtures thereof.

5 11. The method according to claim 1, wherein the subject is in need of the prevention or treatment of an otic disorder or otic-disorder-related complication.

 12. The method according to claim 1, wherein the subject suffers from or is predisposed to one or more otic disorders selected from the group consisting of otic pain, inflammation, otorrhea, otalgia, fever, otic bleeding, Lermoyez's syndrome, Meniere's disease, vestibular neuronitis, 10 benign paroxysmal positional vertigo, herpes zoster oticus, Ramsay Hunt's syndrome, viral neuronitis, ganglionitis, geniculate herpes, labyrinthitis, purulent labyrinthitis, viral endolymphatic labyrinthitis, perilymph fistulas, noise-induced hearing loss, presbycusis, drug-induced ototoxicity, acoustic neuromas, aerotitis media, infectious myringitis, bullous myringitis, otitis 15 media, otitis media with effusion, acute otitis media, secretory otitis media, serous otitis media, acute mastoiditis, chronic otitis media, otitis externa, otosclerosis, squamous cell carcinoma, basal cell carcinoma, nonchromaffin paragangliomas, chemodectomas, globus jugulare tumors, globus tympanicum tumors, external otitis, perichondritis, aural eczematoid 20 dermatitis, malignant external otitis, subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceous cysts, osteomas, keloids, otalgia, tinnitus, vertigo, tympanic membrane infection, typanitis, otic furuncles, otorrhea, acute mastoiditis, petrositis, conductive and sensorineural hearing loss, epidural abscess, lateral sinus thrombosis, 25 subdural empyema, otitic hydrocephalus, Dandy's syndrome, bullous myringitis, cerumen-impacted, diffuse external otitis, foreign bodies, keratosis obturans, otic neoplasm, otomycosis, trauma, acute barotitis media, acute eustachian tube obstruction, post-otic surgery, postsurgical otalgia, cholesteatoma, conductive and sensorineural hearing loss, 30 epidural abscess, lateral sinus thrombosis, subdural empyema and otitic hydrocephalus.

13. A therapeutic composition comprising a Cox-2 inhibitor and an otic agent.

14. A pharmaceutical composition comprising a Cox-2 inhibitor, an otic agent, and a pharmaceutically acceptable carrier.

5 15. A kit comprising one dosage form comprising a Cox-2 inhibitor and a second dosage form comprising an otic agent.